8-K: OmniAb Q2 Revenue Halves Amid Program Shifts

OmniAb, Inc. reported a significant revenue decline in Q2 2025, with net loss increasing, despite strong partner additions and new technology launches.

Summary

• Revenue for Q2 2025 was $3.9 million, a decrease from $7.6 million in Q2 2024.
• Net loss for Q2 2025 was $15.9 million, or $0.15 per share, compared to a net loss of $13.6 million, or $0.13 per share, in Q2 2024.
• Revenue for the first half of 2025 was $8.1 million, down from $11.4 million in the first half of 2024.
• Net loss for the first half of 2025 was $34.1 million, or $0.32 per share, compared to $32.6 million, or $0.32 per share, in the first half of 2024.
• Cash use in Q2 2025 was $2.0 million.
• As of June 30, 2025, cash, cash equivalents, and short-term investments totaled $41.6 million.
• The company affirmed its 2025 revenue guidance of $20 million to $25 million and costs and operating expense guidance of $85 million to $90 million.
• OmniAb entered into six new license agreements and one asset-based sale in Q2 2025, including a $3 million upfront payment and potential milestones over $170 million from Angelini Pharma.
• The company reached 100 active partners and 381 active programs as of June 30, 2025, with 32 OmniAb-derived programs in clinical development or commercialization.
• The xPloration Partner Access Program was launched in May, a high-throughput single B-cell screening instrument, which was awarded '2025 Best of Show' at the PEGS Boston Conference and Expo.

Sentiment

Score: 5

Explanation: The financial results show a significant decline in revenue and increased net loss, indicating a challenging quarter from a financial performance perspective. However, the company's business development, including reaching 100 active partners, signing new agreements, launching the xPloration program, and the continued progression of partner clinical programs, demonstrates underlying operational strength and future potential. The mixed signals result in a neutral sentiment.

Positives

• Reached 100 active partners, demonstrating strong momentum in partner additions.
• Entered into six new license agreements and one asset-based sale in Q2 2025.
• Secured an upfront payment of $3 million and potential milestones over $170 million plus royalties from the sale of a small molecule program to Angelini Pharma.
• Launched the xPloration Partner Access Program, a new offering with potential to expand and diversify revenue streams, which received the '2025 Best of Show' award.
• Research and development expense decreased by $3.0 million in Q2 2025 and $5.0 million in H1 2025 due to lower share-based compensation, reduced headcount, and lower external expenses.
• General and administrative expense decreased by $0.3 million in Q2 2025 and $0.7 million in H1 2025 due to lower legal fees and share-based compensation.
• Affirmed 2025 financial guidance, including expectations for lower cash use than in 2024.
• Several partner programs advanced, including Immunovant's IMVT-1402 entering Phase 3, Teva's TEV-53408 receiving FDA Fast Track designation, and promising early clinical data for JNJ-5322 (Johnson & Johnson), M9140 (Merck KGaA), and BC3195 (BioCity).

Negatives

• Total revenue for Q2 2025 decreased significantly to $3.9 million from $7.6 million in Q2 2024, a 48.7% decline.
• License and milestone revenue decreased primarily due to a $1.8 million decline in milestone revenue in Q2 2025.
• Service revenue declined primarily due to the discontinuation of a small-molecule ion channel program and related acceleration of non-cash revenue in the prior year period.
• Net loss increased to $15.9 million in Q2 2025 from $13.6 million in Q2 2024.
• Cash, cash equivalents, and short-term investments decreased from $59.434 million at December 31, 2024, to $41.6 million at June 30, 2025, indicating continued cash burn.

Risks

• Future success is dependent on acceptance of the technology platform and technologies by new and existing partners.
• Success relies on the eventual development, approval, and commercialization of products developed by partners, over which the company has no control regarding development plan, regulatory strategy, or commercialization efforts.
• Biopharmaceutical development is inherently uncertain.
• Risks arise from changes in technology.
• The company faces a competitive environment in the life sciences and biotechnology platform market.
• Risks are associated with the quality and timing in manufacturing xPloration instruments and related consumables, and reliance on a limited number of third-party manufacturers and suppliers.
• Failure to maintain, protect, and defend intellectual property rights poses a risk.
• Difficulties with the performance of third parties the company relies on for its business could occur.
• Government healthcare reform, legislative measures, and regulatory developments in the United States and foreign countries could impact the business.
• Unstable market and economic conditions may have serious adverse consequences on the business, financial condition, and stock price.
• The company may use its capital resources sooner than expected.

Future Outlook

OmniAb affirmed its 2025 financial guidance, expecting full-year revenue to be in the range of $20 million to $25 million and costs and operating expenses to be between $85 million and $90 million. The company also anticipates 2025 cash use to be lower than the $38.9 million used in 2024 (excluding ATM issuance), with an expected effective tax rate of approximately 0%. The launch of the xPloration Partner Access Program is expected to expand and diversify revenue streams.

Management Comments

• "Our business is performing very well as we continued our momentum in partner additions in the second quarter, reaching 100 active partners. This is a testament to the strength of our innovative technology platform and to our teams execution, and puts us on pace for one of our strongest years ever in partner adds."
• "Additionally, a recent further streamlining of our operations enhances the scalability and long-term value of our business."
• "Our recent launch of the xPloration Partner Access Program demonstrates our commitment to innovation, customer service and value creation. We are excited about this new offering for our partners and for its potential to expand and diversify our revenue streams."

Industry Context

OmniAb operates in the highly competitive and innovation-driven biotechnology and biopharmaceutical discovery platform market. The launch of its xPloration Partner Access Program, leveraging machine learning and artificial intelligence for high-throughput single B-cell screening, aligns with broader industry trends towards integrating advanced computational methods and automation to accelerate drug discovery. The continued progression of partner programs into later clinical stages, particularly in oncology and autoimmune diseases, reflects the ongoing demand for novel therapeutic candidates and the industry's focus on addressing significant unmet medical needs. The company's business model, based on licensing technology and earning milestones and royalties, is a common approach for platform companies in this sector, aiming to de-risk R&D by partnering with larger pharmaceutical companies.

Comparison to Industry Standards

• JNJ-5322, a next-generation trispecific T-cell redirecting antibody, demonstrated a 100% overall response rate (ORR) at the recommended Phase 2 dose of 100 mg in anti-BCMA/-GPRC5D naive patients with relapsed or refractory multiple myeloma, suggesting ORRs similar to CAR-T therapies but as an off-the-shelf, outpatient therapy.
• M9140, a novel antibody-drug conjugate, showed an ORR of 31% (17.2% confirmed) and median progression-free survival (mPFS) of 6.9 months at 2.8 mg/kg every three weeks in heavily pretreated metastatic colorectal cancer (mCRC) patients, which compares favorably with current monotherapy standard of care (ORRs 1-2%, mPFS 1.9-3.7 months) and recent Phase 3 data with trifluridine-tipiracil + bevacizumab (ORR 6.1%, mPFS 5.6 months) in 3L+ mCRC.

Stakeholder Impact

• Shareholders: Experience a significant decline in revenue and increased net loss, potentially impacting stock price, but also benefit from long-term potential through new partnerships and clinical advancements.
• Partners: Benefit from the launch of the xPloration Partner Access Program and the continued support for their drug development efforts, as evidenced by new license agreements and clinical progress.
• Employees: Impacted by reduced headcount mentioned as a factor in lower R&D expenses, but also benefit from the company's continued innovation and business growth.
• Customers: Gain access to new technologies like xPloration and benefit from OmniAb's expanded partner network and expertise in antibody discovery.

Next Steps

• OmniAb management will host a conference call with accompanying slides on August 6, 2025, at 4:30 p.m. Eastern time to discuss the announcement and answer questions.
• Immunovant will continue recruitment for the Phase 3 study of IMVT-1402 in generalized myasthenia gravis and enrollment in other registrational trials.
• Teva Pharmaceutical will continue Phase 2a and Phase 1 clinical trials for TEV-53408.
• Merck KGaA will continue further development of M9140, including the PROCEADE PanTumor Phase 1b/2 clinical trial.
• BioCity will continue dose optimization and expansion for BC3195.

Key Dates

Recommendation

While the financial results for Q2 2025 show a significant revenue decline and increased net loss, the company's underlying business development is strong, marked by reaching 100 active partners, securing new license agreements with substantial potential milestones, and successfully launching the innovative xPloration platform. The affirmation of full-year guidance, including lower expected cash use, suggests management believes the financial performance will improve. However, the current quarter's financial underperformance warrants caution. An investor should hold to observe if the positive business momentum translates into improved financial metrics in subsequent quarters and if the affirmed guidance is met, particularly given the inherent uncertainties in biopharmaceutical development.

Keywords

Biotechnology, Antibody Discovery, Drug Development, SEC Filing, Financial Results, Biopharma, Therapeutics, Clinical Trials, AI in Biotech, Machine Learning, Antibody-Drug Conjugate, Oncology, Autoimmune Disease